Investigating how TDP-43 protein aggregates contribute to ALS and frontotemporal dementia
Role of oligomeric TDP-43 aggregate intermediates in ALS and frontotemporal dementia
This study is looking at how a protein called TDP-43 clumps together in the brain, which is important for understanding diseases like ALS and frontotemporal dementia, and aims to find ways to stop or fix this clumping to help improve treatments for people with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10789852 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind the aggregation of TDP-43 protein, which is linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). By studying the formation of early-stage oligomers of TDP-43, the researchers aim to uncover how these aggregates lead to neurotoxicity and disease progression. The study involves using cellular models and tissue samples from ALS and FTD patients to identify the presence of these oligomers and their role in cellular stress responses. The ultimate goal is to develop strategies to prevent or reverse TDP-43 aggregation, potentially leading to new therapeutic approaches for these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with ALS, frontotemporal dementia, or Alzheimer's disease who are interested in contributing to advancements in understanding these conditions.
Not a fit: Patients with other forms of dementia or neurological disorders unrelated to TDP-43 aggregation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or halt the progression of ALS and frontotemporal dementia.
How similar studies have performed: Previous research has shown promising results in understanding protein aggregation in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ayala, Yuna — Saint Louis University
- Study coordinator: Ayala, Yuna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.